MediciNova is a biopharmaceutical company. Co. is focusing its development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction and prevention of acute respiratory distress syndrome, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. Co.'s pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. We show 57 historical shares outstanding datapoints in our MNOV shares outstanding history coverage, used to compute MNOV market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MNOV market cap history over the course of time is important for investors
interested in comparing MNOV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MNOV versus a peer is one thing; comparing
MNOV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MNOV can fluctuate over the course of history.
With this page we aim to empower investors researching MNOV by allowing them to research the MNOV market cap history. |
Free MNOV Email Alerts:
Video: The Importance of Market Cap
